Some of the detected mutations, albeit at low frequency, have not been previously reported in CUPs, including cKIT mutations, but may be of clinical relevance for the patients with refractory, metastatic disease, as exemplified by a case report where a patient with an activating KIT mutation and protein overexpression was successfully treated with sunitinib [14]. This evidence concerns the gene KIT and metastatic neoplasm.